GLYC - GlycoMimetics, Inc.
11.23 0.00 (0.00%)
After hours: 4:10PM EDT
| Previous Close | 11.12 |
| Open | 11.19 |
| Bid | 11.25 x 800 |
| Ask | 11.26 x 900 |
| Day's Range | 10.84 - 11.44 |
| 52 Week Range | 8.29 - 17.78 |
| Volume | 130,665 |
| Avg. Volume | 197,257 |
| Market Cap | 484.925M |
| Beta (3Y Monthly) | 2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.18 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.80 |
- Business Wire•26 days ago
GlycoMimetics to Present at Jefferies 2019 Healthcare Conference
GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a corporate update at the Jefferies 2019 Healthcare Conference, on June 5 at 2:00 p.m.
- Thomson Reuters StreetEvents•last month
Edited Transcript of GLYC earnings conference call or presentation 2-May-19 12:30pm GMT
Q1 2019 GlycoMimetics Inc Earnings Call
- Insider Monkey•last month
Here’s What Hedge Funds Think About GlycoMimetics, Inc. (GLYC)
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- Business Wire•2 months ago
GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease
GlycoMimetics, Inc. (GLYC) today announced that patient enrollment has been completed in the Phase 3 RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) clinical trial, which is evaluating the efficacy and safety of rivipansel for the acute treatment of vaso-occlusive crisis (VOC) in sickle cell disease (SCD). In 2011, GlycoMimetics and Pfizer Inc. (PFE) entered into a worldwide license agreement for the development and, if approved by applicable regulatory authorities, commercialization of rivipansel. Since completion of the Phase 2 clinical trial, Pfizer, has been responsible for clinical development of rivipansel, including the RESET clinical trial.
Motley Fool•2 months agoGlycoMimetics (GLYC) Q1 2019 Earnings Call Transcript
GLYC earnings call for the period ending March 31, 2019.
- Associated Press•2 months ago
GlycoMimetics: 1Q Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 33 cents. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...
- Business Wire•2 months ago
GlycoMimetics Reports First Quarter 2019 Results and Recent Operational Highlights
ROCKVILLE, Md.-- -- Enrolled first patient in National Cancer Institute -sponsored Phase 3 trial of uproleselan in older adults with previously untreated acute myeloid leukemia Announced plans to initiate a trial of GMI-1359 in individuals with breast cancer in collaboration with the Duke Cancer Institute Established transition plan to new Chairman of Board of Directors GlycoMimetics, Inc. today reported ...
- ACCESSWIRE•2 months ago
GlycoMimetics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 2, 2019 / GlycoMimetics, Inc. (NASDAQ: GLYC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 2, 2019 at 8:30 AM Eastern ...
- Business Wire•2 months ago
GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel
GlycoMimetics, Inc. (GLYC) today announced the addition of two senior executives to its executive management team. Eric Feldman, M.D., a specialist in leukemia and bone marrow disorder therapies, has been appointed Vice President of Clinical Development. Christian Dinneen-Long, an attorney with deep experience in the biotechnology industry, has been appointed Vice President and Corporate Counsel.
- Business Wire•2 months ago
GlycoMimetics to Report First Quarter 2019 Financial Results on May 2, 2019
GlycoMimetics, Inc. announced today that it will host a conference call and webcast to report its first-quarter 2019 financial results on Thursday, May 2, 2019, at 8:30 a.m.
- Business Wire•2 months ago
GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML
GlycoMimetics, Inc. (GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a Cooperative Research and Development Agreement (CRADA) between GlycoMimetics and the National Cancer Institute (NCI), part of the National Institutes of Health. The second in a series of trials designed to evaluate uproleselan across the continuum of care in AML, this NCI-sponsored study is evaluating the addition of uproleselan to a standard cytarabine/daunorubicin regimen (7&3) in older adults with previously untreated AML who are suitable for intensive chemotherapy.
- Business Wire•2 months ago
GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359
Data shows that E-selectin is key to tumor growth and metastasis to bone and provides further support for upcoming clinical trial in patients with metastatic breast cancer
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of GLYC earnings conference call or presentation 6-Mar-19 1:30pm GMT
Q4 2018 GlycoMimetics Inc Earnings Call
- Business Wire•2 months ago
GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359
GlycoMimetics, Inc. (GLYC) today announced plans to initiate a clinical trial of GMI-1359 in breast cancer patients whose tumors have spread to bone. GMI-1359 is a dual function antagonist that targets both E-selectin and CXCR4, both of which are involved in tumor trafficking and metastatic spread.
- Business Wire•3 months ago
GlycoMimetics to Present at Upcoming Investor Conferences
GlycoMimetics, Inc. today announced that senior management will present corporate updates at two upcoming investor conferences in April. Details are as follows:
- Business Wire•4 months ago
GlycoMimetics to Present at the Cowen and Company 39th Annual Health Care Conference 2019
GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen and Company 39th Annual Health Care Conference in Boston, on Tuesday, March 12, 2019, at 9:20 a.m.
- Simply Wall St.•4 months ago
Did GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Sell Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are moreRead More...
Motley Fool•4 months agoGlycoMimetics Inc (GLYC) Q4 2018 Earnings Conference Call Transcript
GLYC earnings call for the period ending December 31, 2018.
- Business Wire•4 months ago
GlycoMimetics Reports Fourth Quarter and Year-End 2018 Results
ROCKVILLE, Md.-- -- Initiated first company-sponsored Phase 3 pivotal trial of uproleselan in relapsed/refractory acute myeloid leukemia at sites in U.S., Europe, Canada and Australia Provided oral presentation at the American Society of Hematology Annual Meeting in December 2018 on the final clinical outcomes data and subgroup analyses from the Phase 1/2 AML trial of uproleselan, which supports the ...
- Business Wire•4 months ago
GlycoMimetics Announces Transition Plan for Board of Directors
Current Board Chair Jim Barrett, who has held the role since the company’s inception, will not seek re-election as he retires from the Board of Directors and scales back participation in several organizations. Current GlycoMimetics Board Member Tim Pearson will become Board Chair as of the close of the company’s annual meeting on May 17, 2019.
- Business Wire•4 months ago
GlycoMimetics to Report Fourth Quarter and Year-End 2018 Financial Results on March 6, 2019
GlycoMimetics, Inc. (GLYC) announced today that it will host a conference call and webcast to report its fourth quarter and fiscal year 2018 financial results on Wednesday, March 6, 2018, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 5072004. A webcast replay will be available via the “Investors” tab on the GlycoMimetics website for 30 days following the call.
- GlobeNewswire•4 months ago
Detailed Research: Economic Perspectives on Waddell & Reed Financial, Kennametal, Automatic Data Processing, Trustmark, Eagle Bulk Shipping, and GlycoMimetics — What Drives Growth in Today's Competitive Landscape
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Simply Wall St.•6 months ago
Here’s What We Think About GlycoMimetics, Inc.’s (NASDAQ:GLYC) CEO Pay
Rachel King has been the CEO of GlycoMimetics, Inc. (NASDAQ:GLYC) since 2003. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider Read More...
- Business Wire•7 months ago
GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates
GlycoMimetics, Inc. (GLYC) shared at the 60th American Society of Hematology (ASH) Annual Meeting yesterday two posters with preclinical data presentations: on GMI-1687, the company’s highly potent E-selectin antagonist that is bioavailable via subcutaneous administration, and GMI-1757, the company’s dual-function E-selectin/galectin-3 antagonist. “The new preclinical data presented at ASH underscore GlycoMimetics’ commitment to pioneering advances in the field of glycobiology and to rationally designing innovative drug candidates that address areas of significant unmet medical need,” said John Magnani, Ph.D., Senior Vice President and Chief Scientific Officer.
